A next-generation Biotechnology company creating off-the-shelf cellular medicines for Cancer, Infectious Diseases, and Degenerative Diseases. (NASDAQ:CELU)
RELEASE: Celularity secures strategic license deal worth up to $35M, strengthening capital position while focusing on longevity therapeutics.
Read the full release here:
https://t.co/FAWJfTEwoH
RELEASE: Celularity Inc. (Nasdaq: CELU) Receives $12.2 Million from Sale of New Jersey Net Operating Losses
Read the full release here: https://t.co/dj5nl7IELT
RELEASE: Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations
Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz.
https://t.co/wanvhwb5u0
RELEASE: Celularity announces the closing of its previously disclosed financing transactions with Philip A. Barach, co-founder and former president of DoubleLine Capital LP.
https://t.co/EOKIjCH7BZ
RELEASE: Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision
READ THE FULL RELEASE HERE:
https://t.co/UOodUZjgF3
Big announcement! We are excited to be part of DefEYE’s focused expansion into the ophthalmic space and to demonstrate the transformative power of placental-derived regenerative biologic solutions.
Read the full release here: https://t.co/gTfopZhJNk
Exciting news! Celularity Phase 2 clinical trial results published on the safety and efficacy of placenta-derived cells for diabetic foot ulcers complicated by Peripheral Artery Disease.
Read the full release here: https://t.co/xZR7NAdRBP
We are pleased to report that we have filed our Form 10-Q quarterly reports for the first and the second quarters 2025. This comes on the heels of the recently announced retirement of all $32.0 million senior secured debt.
Read the full release here:
https://t.co/O7VSCBZTLY
We have successfully monetized Celularity’s intellectual property assets to retire the Company’s senior secured debt in its entirety while retaining exclusive use of the assets for our cell therapy, advanced biomaterials, and biobanking businesses.
https://t.co/egoE03VLBq
RELEASE: Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law
Read it here:
https://t.co/PL4iZyihmu
Advancing Ocular Surface Reconstruction: Our DDHAM-3L technology, with its unique biological properties, offers a promising platform for delivering patient-specific, iPSC-derived LSCs to restore vision and improve patient outcomes. https://t.co/ujDA5E4ri6
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
Read the full release here: https://t.co/SFPNrYqN7b
An important publication form our team in Frontiers in Immunology: Senescence, NK Cells, and Cancer.
Read the full release - with link to the publication - here:
https://t.co/a0pY6J7CtS
Excited to receive FDA Tissue Reference Group recommendation letters on the newest additions to our portfolio of human placental-derived biomaterials. Full story here: https://t.co/Ho8JOH1MCy
We are delighted to announce a strategic collaboration with BlueSphere Bio, Inc., which will bring together our core strengths in cell manufacturing, process development and BSB’s development of novel cell therapies to treat high risk leukemias. https://t.co/23dZ36Hkqx
Celularity Founder and CEO Dr. Robert Hariri to be a Keynote Speaker at the Longevity Med Summit this May, discussing cellular therapies for human performance and longevity.
#longevity#stemcells
https://t.co/Zsy02wKA7P
A great feature in Drug Target Review's Beyond the Lab Report on the work Celularity is doing in the realm of stem cell therapies. (Found on page 6.)
https://t.co/CPHfzvtCdJ
Celularity, Inc. is proud to be a member of the MASS Coalition, a group of business leaders who together are working with the new administration to prevent amputation and other complications associated with Diabetes and Cardiovascular disease. https://t.co/BFpB01qU3X
Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million!
Read the full release here:
https://t.co/7F5Twpn41P